ARCHES - The role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of high and low disease volume and risk groups

Conference Paper

Full Text

Duke Authors

Cited Authors

  • Stenzl, A; Szmulewitz, RZ; Petrylak, DP; Holzbeierlein, J; Villers, A; Azad, AA; Alcaraz, A; Alekseev, BY; Iguchi, T; Shore, ND; Rosbrook, B; Baron, B; Haas, GP; Morlock, R; Ramaswamy, K; Armstrong, AJ

Published Date

  • October 1, 2019

Published In

Volume / Issue

  • 30 /

Start / End Page

  • 332 - +

Published By


  • 2

Electronic International Standard Serial Number (EISSN)

  • 1569-8041

International Standard Serial Number (ISSN)

  • 0923-7534

Conference Name

  • 44th Congress of the European-Society-for-Medical-Oncology (ESMO)

Conference Location

  • Barcelona, SPAIN

Conference Start Date

  • September 27, 2019

Conference End Date

  • October 1, 2019